Medicare Payments For High-Cost ESRD Drugs May Be Reconsidered In Future Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
Automatic bundling remains for now, but CMS acknowledges concerns about potentially stifling innovation.
You may also be interested in...
Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs
More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.
Emerging Dialysis Drugs Will Face Medicare Reimbursement Challenges
Navigating Medicare's complicated bundled payment system could be tricky for new class of anemia drugs, the HIF prolyl hydroxylase inhibitors, which may start to reach the market for dialysis patients in 2019.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.